ARO-ATXN2
/ Arrowhead, Sarepta Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 21, 2025
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Trial completion date: Sep 2026 ➔ Dec 2026 | Trial primary completion date: Sep 2026 ➔ Dec 2026
Trial completion date • Trial primary completion date • Ataxia • Movement Disorders
1 to 1
Of
1
Go to page
1